Prospective evaluation of the prognostic relevance of molecular staging for urothelial carcinoma

Cancer

Volumn 107, Issue 1, 2006, Pages 60-66

  Copp, Hillary L ^a   Chin, Joseph L ^b   Conaway, Mark ^c   Theodorescu, Dan ^a,d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Bladder neoplasms; Clinical trial; Metastasis; Tumor markers

Indexed keywords

MESSENGER RNA; TUMOR MARKER; UNCLASSIFIED DRUG; UROPLAKIN; UROPLAKIN II;

ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CYSTECTOMY; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 33745327043     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21953     Document Type: Article

References (24)

1. Vieweg J, Gschwend JH, Herr HW, et al. The impact of primary stage on survival in patients with lymph node positive bladder cancer. J Urol. 1999;161:72-76.
2. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666-675.
3. Li SM, Zhang ZT, Chan S, et al. Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder. J Urol. 1999;162:931-935.
4. Sun TT, Liang FX, Wu XR. Uroplakins as markers of urothelial differentiation. Adv Exp Med Biol. 1999;462:7-18; discussion 103-114.
5. Lobban ED, Smith BA, Hall GD, et al. Uroplakin gene expression by normal and neoplastic human urothelium. Am J Pathol. 1998;153:1957-1967.
6. Olsburgh J, Harnden P, Weeks R, et al. Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. J Pathol. 2003;199:41-49.
7. Osman I, Kang M, Lee A, et al. Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients. Int J Cancer. 2004;111:934-939.
8. Hirata H, Hisatomi H, Kawakita M, et al. Genetic detection for hematogenous micrometastasis in patients with various types of malignant tumors using Uroplakin II derived primers in polymerase chain reaction. Oncol Rep. 2003;10:963-966.
9. Lu JI, Kakehi Y, Takahashi T, et al. Detection of circulating cancer cells by reverse transcription-polymerase chain reaction for uroplakin II in peripheral blood of patients with urothelial cancer. Clin Cancer Res. 2000;6:3166-3171.
10. Seraj MJ, Thomas AR, Chin JL, et al. Molecular determination of perivesical and lymph node metastasis after radical cystectomy for urothelial carcinoma of the bladder. Clin Cancer Res. 2001;7:1516-1522.
11. Retz M, Lehmann J, Szysnik C, et al. Detection of occult tumor cells in lymph nodes from bladder cancer patients by MUC7 nested RT-PCR. Eur Urol. 2004;45:314-319.
12. Sobin LH. TNM, 6th edition. New developments in general concepts and rules. Semin Surg Oncol. 2003;21:19-22.
13. Berry G. The analysis of mortality by the subject-years method. Biometrics. 1983;39:173-184.
14. Madersbacher S, Thalmann GN, Fritsch JC, et al. Is eligibility for a chemotherapy protocol a good prognostic factor for invasive bladder cancer after radical cystectomy? J Clin Oncol. 2004;22:4103-4108.
15. Lerner SP, Skinner DG, Lieskovsky G, et al. The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. J Urol. 1993;149:758-764; discussion 64-65.
16. Abdel-Latif M, Abol-Enein H, El-Baz M, et al. Nodal involvement in bladder cancer cases treated with radical cystectomy: incidence and prognosis. J Urol. 2004;172:85-89.
17. Theodorescu D, Frierson HF Jr. When is a negative lymph node really negative? Molecular tools for the detection of lymph node metastasis from urological cancer. Urol Oncol. 2004;22:256-259.
18. Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003;21:690-696.
19. Kurahashi T, Hara I, Oka N, et al. Detection of micrometastases in pelvic lymph nodes in patients undergoing radical cystectomy for locally invasive bladder cancer by real-time reverse transcriptase-PCR for cytokeratin 19 and uroplakin II. Clin Cancer Res. 2005;11:3773-3777.
20. Bochner BH, Clio D, Herr HW, et al. Irrespectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping. J Urol. 2004; 172:1286-1290.
21. von der Maase H, Hansen SW, Roberts JT, el al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068-3077.
22. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet. 1999;354:533-540.
23. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859-866.
24. Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. 2001;19:4005-4013.